Press Releases

  • Interim report July 1 to September 30, 2017

    October 26, 2017 10:21 (CEST)

  • Cyxone's T20K development drug in 87 different pharmacological tests

    October 26, 2017 10:07 (CEST)

    In co-operation with Taiwan-based Eurofins Panlabs Discovery Services, Cyxone has investigated whether T20K has the capacity to influence receptors or other cellular functions to shed light on the substance's potential side effects.

  • Cyxone to research additional autoimmune conditions

    October 13, 2017 17:02 (CEST)

    In collaboration with the Medical University of Vienna, Cyxone is set to conduct a study into inflammatory bowel disease involving a cyclotide in established animal models. The study will begin early in 2018.

  • Regarding Patent Applications

    October 6, 2017 15:30 (CEST)

    Cyxone has licensed patent applications at various stages of approval in Europe, North America and Australia. In the US, our patent is approved and in other markets patent applications are well on the way to being approved. In Australia, our patent application was accepted in July, since when the company has submitted a final version and paid the required approval fee.

  • Additional information: Cyxone to explore options for faster market approval

    October 5, 2017 18:50 (CEST)

    Due to the interview conducted with Cyxone's CEO by BioStock/Monocl on Thursday, September 28, the company wishes to clarify references made about the extent to which two Phase 2 trials may be equated with a Phase 3 trial.

  • Cyxone's TO 2 series warrant options exercised to around 98.7%

    October 5, 2017 13:00 (CEST)

    The subscription period to purchase warrants in TO 2 ended on September 29, 2017, and during the period, 2,467,119 warrant options were exercised for the equivalent number of shares, corresponding to a subscription ratio of around 98.7%. Cyxone thereby receives some SEK 12.3 million before issue costs.

  • Interim report 2017-01-01 to 2017-06-30

    August 30, 2017 09:39 (CEST)

  • Cyxone signs acquisition agreement for candidate drug in Phase 2

    June 14, 2017 09:00 (CEST)

    Cyxone signs acquisition agreement for candidate drug in Phase 2 Cyxone can announce today that the company has signed an agreement pertaining to the exclusive rights to acquire the clinical candidate drug Rabeximod from OxyPharma AB. The transaction has been structured so as to minimise the impact on Cyxone's cash flow by offering the seller 1,916,372 shares, (one million, nine hundred and sixteen thousand, three hundred and seventy two shares amounting to a dilution of 12.5 per cent), as well as royalty rights amounting to ten (10) per cent of future net earnings from Rabeximod. Cyxone will call an extraordinary general meeting to seek shareholder approval for a directed new share issue. This will pave the way for the acquisition and a Phase 2b-study in rheumatoid arthritis.

  • Cyxone enters into co-operation agreement with University of Queensland

    June 7, 2017 16:17 (CEST)

    Cyxone AB and the University of Queensland in Australia are launching a co- operation agreement to continue studies into the effects of Cyxone's T20K development substance in combating MS.

  • Cyxone in strategic development co-operation with European CRO

    May 18, 2017 09:19 (CEST)

    Cyxone can announce today that it has established a long-term strategic co-operation agreement with Sourcia, a clinical contract research organization (CRO) with offices in Belgium, Germany, and the Netherlands.